David Smith
Project Manager
David joined the Oxford Vaccine Group in May 2018. He has a Ph. D in molecular biology from the University of Newcastle-Upon-Tyne. He conducted postdoctoral studies with the University of Oxford and the University of Nebraska Medical Center before Returning to Oxford. Following a spell as a researcher with the NHSBT he began clinical trial management in the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences before moving to OVG. David’s role in OVG is to work closely with the study team to ensure the delivery of projects on time, within budget and in compliance with regulatory requirements.
Recent publications
-
Storage of washed or irradiated red cells in AS-7 improves their in vitro characteristics.
Journal article
Proffitt S. et al, (2015), Vox Sang, 109, 203 - 213
-
Loss of Fibulin-2 Expression Is Associated with Breast Cancer Progression
Journal article
Yi C-H. et al, (2007), The American Journal of Pathology, 170, 1535 - 1545
-
Metallothioneins and resistance to cisplatin and radiation in prostate cancer
Journal article
Smith DJ. et al, (2006), Urology, 67, 1341 - 1347
-
Tissue transglutaminase interacts with protein kinase A anchor protein 13 in prostate cancer☆
Journal article
Lewis TE. et al, (2005), Urologic Oncology: Seminars and Original Investigations, 23, 407 - 412
-
E-cadherin phosphorylation by protein kinase D1/protein kinase C{mu} is associated with altered cellular aggregation and motility in prostate cancer.
Journal article
Jaggi M. et al, (2005), Cancer Res, 65, 483 - 492